ÀûÀ´¹Ù·½ÍøÕ¾w66ÀûÀ´AG·¢²ÆÍø²»´í
ÁªÏµ·½Ê½
ÁªÏµµç»°£º
ÁªÏµ´«Õ棺
µç×ÓÓÊÏ䣺
ÁªÏµµØÖ·£º
µ±Ç°Î»Ö㺠> ÀûÀ´¹Ù·½ÍøÕ¾w66ÀûÀ´AG·¢²ÆÍø²»´í > ÀûÀ´¹Ù·½ÍøÕ¾w66ÀûÀ´AG·¢²ÆÍø²»´í

¹ú¼ÒÎÀ½¡Î¯Í¨±¨36Æðҽѧ¿ÆÑгÏÐ۸µ÷²é½á¹û

×÷Õߣº admin À´Ô´£º δ֪ ·¢²¼Ê±¼ä£º2022-01-04
htmlÄ£°æ¹ú¼ÒÎÀ½¡Î¯Í¨±¨36Æðҽѧ¿ÆÑгÏÐ۸µ÷²é½á¹û

¾Ý¹ú¼ÒÎÀ½¡Î¯ÍøÕ¾ÏûÏ¢£¬ÎÀ½¡Î¯Í¨±¨²¿·Ö»ú¹¹Ò½Ñ§¿ÆÑгÏÐ۸¼þµ÷²é´¦Àí½á¹û¡£ÏÖ½«²¿·ÖÎÀÉú½¡¿µÐÐÕþ²¿ÃÅËùÊôÒ½ÁÆ»ú¹¹½üÆÚ¹«¿ªÍ¨±¨µÄҽѧ¿ÆÑгÏÐ۸¼þµ÷²é´¦Àí½á¹û×ªÔØÈçÏ£º

Ò»¡¢Õã½­Ê¡Á¢Í¬µÂÒ½Ôº¹ùÏþÁáΪͨѶ×÷Õß¡¢Õã½­Ê¡Á¢Í¬µÂÒ½ÔºÖÜ·ïÈçΪµÚÒ»×÷Õß¡¢ºþÖÝÊÐÖÐÐÄÒ½ÔºÅËÖÎÆ½Îª¹²Í¬µÚÒ»×÷Õß·¢±íµÄÂÛÎÄLong noncoding RNA DLX6-AS1 functions as a competing endogenous RNA for miR-577 to promote malignant development of colorectal cancer£¬¾­²é£¬Ïµ´æÔÚ±àÔìÑо¿¹ý³Ì¡¢Î¥·´¿ÆÑÐÂ×Àí¼°²»µ±ÊðÃûµÄѧÊõ²»¶ËÐÐΪ¡£

1.Õã½­Ê¡Á¢Í¬µÂÒ½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

£¨1£©¶ÔͨѶ×÷Õß¹ùÏþÁ᣺ȡÏûÆäÖÐÎ÷Ò½½áºÏÖ÷ÖÎҽʦרҵ¼¼ÊõÖ°ÎñƸÈÎ,רҵ¼¼Êõ¸ÚλÓÉÊ®¼¶½µÆ¸ÎªÊ®Ò»¼¶£¬2ÄêÄÚ²»µÃ½úÉýרҵ¼¼ÊõÖ°Îñ¼°×¨Òµ¼¼Êõ¸ÚλµÈ¼¶,3ÄêÄÚÄê¶È¿¼ºË²»µÃÆÀΪÓÅÐãµÈ´Î£¬5ÄêÄÚ²»µÃÉ걨¸÷¼¶¸÷ÀàÈ˲š¢¿ÆÑÐÏîÄ¿£¬ÊÕ»ØÏà¹Ø¿ÆÑн±ÀøºÍ°æÃæ·Ñ£¬½ëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£

£¨2£©¶ÔµÚÒ»×÷ÕßÖÜ·ïÈ磺רҵ¼¼Êõ¸ÚλÓɰ˼¶½µÆ¸Îª¾Å¼¶£¬2ÄêÄÚ²»µÃ½úÉýרҵ¼¼ÊõÖ°Îñ¼°×¨Òµ¼¼Êõ¸ÚλµÈ¼¶,³·Ïú2019ÄêÄê¶È¿¼ºËÓÅÐãµÈ´Î£¬3ÄêÄÚÄê¶È¿¼ºË²»µÃÆÀΪÓÅÐãµÈ´Î£¬5ÄêÄÚ²»µÃÉ걨¸÷¼¶¸÷ÀàÈ˲š¢¿ÆÑÐÏîÄ¿£¬ÊÕ»ØÏà¹Ø¿ÆÑн±ÀøºÍ°æÃæ·Ñ£¬ÔðÁî¼ì²é¡¢½ëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£

£¨3£©¶ÔÆäËû×÷ÕßÉò·æ¡¢»ÆÂ·ÇÅ¡¢²Ìçæ£ºÈ¡ÏûÉ걨¸÷¼¶¸÷ÀàÈ˲š¢¿ÆÑÐÏîÄ¿×ʸñ1Ä꣬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£

2.ºþÖÝÊÐÖÐÐÄÒ½Ôº¶Ô¹²Í¬µÚÒ»×÷ÕßÅËÖÎÆ½×÷³öÈçÏ´¦Àí£ºÈ¡ÏûÉ걨¸÷Àà¸÷¼¶¿ÆÑÐÏîÄ¿×ʸñ1Äê¡£

£¨Í¨±¨Á´½Ó£º£©

Èý¡¢Õã½­Ê¡Äþ²¨ÊеھÅÒ½ÔººÎÑǹâΪͨѶ×÷Õß¡¢ÓàÐã¹úΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄLong non-coding RNA PVT1 functions as an oncogene in human colon cancer through miR-30d-5p/RUNX2 axis£¬¾­²é£¬Ïµ´æÔÚÊý¾ÝÔì¼ÙµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦Àí£º

1.¶ÔͨѶ×÷ÕߺÎÑǹ⣺ȡÏûÉ걨¿Æ¼¼¼Æ»®£¨»ù½ð£©ÏîÄ¿¼°¿Æ¼¼±¨½±×ʸñ£¬µ£ÈÎÂÛÎÄ¡¢¿ÎÌâ¡¢»ù½ð¡¢±¨½±µÈÆÀÉóר¼Ò×ʸñ5Äꣻ¿ÆÑгÏÐŽëÃã̸»°¼°ÊéÃæ¼ì²é£»¿Û·£¼¨Ð§¹¤×Ê3¸öÔ£»È¡Ïûµ±ÄêÆÀÏÈÆÀÓÅ×ʸñ£»Í¨±¨ÅúÆÀ¡£

2. ¶ÔµÚÒ»×÷ÕßÓàÐã¹ú£ºÈ¡ÏûÖ°³ÆÖ°Îñ½úÉý×ʸñ3ÄꣻȡÏûÉ걨¿Æ¼¼¼Æ»®£¨»ù½ð£©ÏîÄ¿¼°¿Æ¼¼±¨½±×ʸñ£¬µ£ÈÎÂÛÎÄ¡¢¿ÎÌâ¡¢»ù½ð¡¢±¨½±µÈÆÀÉóר¼Ò×ʸñ5Äꣻ¿ÆÑгÏÐŽëÃã̸»°¼°ÊéÃæ¼ì²é£»¿Û·£¼¨Ð§¹¤×Ê3¸öÔ£»ÊջذæÃæ·Ñ±¨ÏúºÍ¿ÆÑн±Àø£»È¡Ïûµ±ÄêÆÀÏÈÆÀÓÅ×ʸñ£»Í¨±¨ÅúÆÀ¡£

£¨Í¨±¨Á´½Ó£º£©

ËÄ¡¢É½¶«Ê¡µÂÖÝÊÐÈËÃñÒ½ÔºÕÅޱޱΪµÚÒ»¼æÍ¨Ñ¶×÷Õß·¢±íµÄÂÛÎÄLong non-coding RNA-ROR aggravates myocardialischemia/reperfusion injury¡£¾­²é£¬Ïµ´æÔÚÂòÂôÂÛÎĵÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º

1.¶ÔµÚÒ»¼æÍ¨Ñ¶×÷ÕßÕÅÞ±Þ±£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬¹«¿ªÍ¨±¨ÅúÆÀ£¬È¡Ïû½úÉýÖ°ÎñÖ°³Æ¡¢É걨¿Æ¼¼¼Æ»®£¨×¨Ïî¡¢»ù½ðµÈ£©ÏîÄ¿µÈ×ʸñ5Ä꣬¼ÇÈë¿ÆÑгÏÐÅÐÅϢϵͳ¡£

2.¶ÔµÚ¶þ×÷ÕßÀîÓ¨¡¢µÚÈý×÷ÕßÍõÅô£º¿ÆÑгÏÐŽëÃã̸»°£¬È¡Ïû½úÉýÖ°ÎñÖ°³Æ¡¢É걨¿Æ¼¼¼Æ»®£¨×¨Ïî¡¢»ù½ðµÈ£©ÏîÄ¿µÈ×ʸñ1Äê¡£

£¨Í¨±¨Á´½Ó£º£©

Î塢ɽ¶«Ê¡ÁÙÒÊÊÐÈËÃñÒ½ÔºÕŽ¨»ªÎªµÚÒ»×÷Õߣ¬ÁÙÒÊÊÐÈËÃñÒ½ÔºÕÔ·æ¡¢ÁÙÒÊÊÐÀ¼ÁêÏØÈËÃñÒ½ÔºÀîÓñ¹úΪͨѶ×÷Õß·¢±íÂÛÎÄCurcumin Inhibits Proliferation and Soluble Collagen Synthesis of NIH/3T3 Cell Line by Modulation of miR-29a and via ERK1/2 and -catenin Pathways£¬¾­²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôµÄѧÊõ²»¶ËÐÐΪ¡£

1.ÁÙÒÊÊÐÈËÃñÒ½Ôº¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦ÀíÈçÏ£º

£¨1£©¶ÔµÚÒ»×÷ÕßÕŽ¨»ª£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å; ¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£

£¨2£©¶ÔͨѶ×÷ÕßÕԷ棺¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å; ¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£

£¨3£©¶ÔÆäËû×÷ÕßËÎ÷¡¢Àîά·å£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬È¡ÏûÆä1ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡ÏûÆä1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1Äê¡£

2,»·ÑÇag88µÇ¼.ÁÙÒÊÊÐÀ¼ÁêÏØÈËÃñÒ½Ôº¶ÔͨѶ×÷ÕßÀîÓñ¹ú£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬È¡Ïû2020Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£

£¨Í¨±¨Á´½Ó£ºMitigates Hydrogen Peroxide-Induced Injury by Enhancement of microRNA-27a in Human Trabecular Meshwork Cells£¬¾­²é£¬Ïµ´æÔÚÂÛÎÄÂòÂô£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃËùÓÐ×÷ÕßÖªÇéͬÒâ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦ÀíÈçÏ£º

1.¶ÔµÚÒ»×÷ÕßÕÔ¾ü£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å; ¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£

2.¶ÔͨѶ×÷ÕßÕžêÃÀ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å; ¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£

£¨Í¨±¨Á´½Ó£ºinhibits growth and migration of gastrointestinal stromal tumor cell line GIST-T1 by up-regulation of miR-449a£¬¾­²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôÐÐΪ£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃËùÓÐ×÷ÕßÖªÇéͬÒâ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦ÀíÈçÏ£º

1.¶ÔµÚÒ»×÷ÕßѦ·½Ï²£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å£»¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£

2.¶ÔͨѶ×÷ÕßÌï·å£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä1ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1Äꣻ³·¸å¡£

3.¶ÔÆäËû×÷ÕßÁõÕ×ϼ¡¢Ð콨¡¢ÐìÏþ¹â¡¢³ÂÐËÌ¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£

£¨Í¨±¨Á´½Ó£º.cn/News/Articles?id=869isPreview=truearticleMappingId=code=3ce05444b2ff2ea0£©

°Ë¡¢É½¶«Ê¡ÁÙÒÊÊÐÖÐÐÄÒ½Ôº³Ì×ÓÃ÷ΪµÚÒ»×÷Õß¡¢ºîÊËÕñΪͨѶ×÷Õß·¢±íÂÛÎÄK-Ras-ERK1/2 accelerates lung cancer cell development via mediating H3K18ac through the MDM2-GCN5-SIRT7 axis£¬¾­²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôÐÐΪ£¬ÇÒδ°´¹æ·¶³ÌÐò»ñµÃËùÓÐ×÷ÕßÖªÇéͬÒâ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦ÀíÈçÏ£º

1.¶ÔµÚÒ»×÷Õß³Ì×ÓÃ÷£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä6ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ6Äꣻ³·¸å£»¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£

2.¶ÔͨѶ×÷ÕߺîÊËÕñ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä1ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1Äꣻ³·¸å¡£

3.¶ÔÆäËû×÷ÕßÀîÐã·å¡¢ÎäÓñ±ø¡¢ËïÒã¡¢Áõ±ù£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£

£¨Í¨±¨Á´½Ó£º.cn/News/Articles?id=869isPreview=truearticleMappingId=code=3ce05444b2ff2ea0£©

¾Å¡¢É½¶«Ê¡ÁÙÒÊÊи¾Ó×±£½¡ÔºÀî»ÛΪͨѶ×÷Õß¡¢ÁÙÒÊÊÐÈËÃñҽԺѦÓÀÕäΪµÚÒ»×÷Õß·¢±íÂÛÎÄAngelica polysaccharide moderates hypoxia-evoked apoptosis and autophagy in rat neural stem cells by downregulation of BNIP3£¬¾­²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôÐÐΪ£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃËùÓÐ×÷ÕßÖªÇéͬÒâ¡£

1.ÁÙÒÊÊи¾Ó×±£½¡Ôº¶ÔͨѶ×÷ÕßÀî»Û×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»È¡ÏûÆä5ÄêÄÚÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ£»³·¸å£»¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£

2.ÁÙÒÊÊÐÈËÃñÒ½Ôº¶ÔµÚÒ»×÷ÕßѦÓÀÕä×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·ÏúÆäÀûÓÿÆÑÐʧÐÅÐÐΪƸÈεĸ±Ö÷ÈÎҽʦ×ʸñ£»³·¸å£»¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£

3.ɽ¶«Ê¡ÃºÌ¿ÁÙÒÊÎÂȪÁÆÑøÔº¶ÔÆäËû×÷ÕßÀ÷×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·ÏúÆäÀûÓÿÆÑÐʧÐÅÐÐΪ»ñµÃ¸±Ö÷ÈÎҽʦ×ʸñ£»³·¸å¡£

£¨Í¨±¨Á´½ÓÖ·£º£©

Ê®¡¢É½¶«Ê¡ÁÙÒÊÊÐÀ¼ÁêÏØÈËÃñÒ½ÔºÐÁÀöºìΪµÚÒ»¼æÍ¨Ñ¶×÷Õß·¢±íÂÛÎÄOverexpression of DJ-1 expressionprotects cardiomyocyte apoptosis inducedby ischemia reperfusion£¬¾­²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôÐÐΪ£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃËùÓÐ×÷ÕßÖªÇéͬÒâ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦ÀíÈçÏ£º

1.¶ÔµÚÒ»¼æÍ¨Ñ¶×÷ÕßÐÁÀöºì£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å£»¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£

2.¶ÔÆäËû×÷ÕßÁõÎľü¡¢ËÎÌΡ¢ÕÅÁÕ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡Ïû2020Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£

£¨Í¨±¨Á´½Ó£º£©

ʮһ¡¢É½¶«Ê¡¼ÃÄþÊеÚÒ»ÈËÃñÒ½ÔºÀî·åΪͨѶ×÷Õß¡¢ÍõΰΰΪµÚÒ»×÷Õß¡¢ºÂÑÒΪ²¢ÁеÚÒ»×÷Õß·¢±íµÄÂÛÎÄNotoginsenoside R1 alleviates high glucose-evoked damage in RSC96 cells through down-regulation of miR-503£¬¾­²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³ÌµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÀî·å£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬Ôð³É¾¡¿ìÁªÏµÔÓÖ¾Éç³·¸å£¬µ³ÄÚ¾¯¸æ¡£

2.¶ÔµÚÒ»×÷ÕßÍõΰΰ£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬µ³ÄÚ¾¯¸æ¡£

3.¶Ô²¢ÁеÚÒ»×÷ÕߺÂÑÒ£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬µ³ÄÚ¾¯¸æ¡£

£¨Í¨±¨Á´½Ó£º£©

Ê®¶þ¡¢É½¶«Ê¡¼ÃÄþÊеÚÒ»ÈËÃñÒ½ÔºÐí·ÉΪͨѶ×÷Õߣ¬×£°®¶«ÎªµÚÒ»×÷Õߣ¬ËïÓ¯Ó¯¡¢ÂíÇï¾ÕΪ²¢ÁеÚÒ»×÷Õß·¢±íµÄÂÛÎÄlncRNA?ATB promotes viability, migration, and angiogenesis in human microvascular endothelial cells by sponging microRNA?195£¬¾­²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³ÌµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÐí·É£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬µ³ÄÚ¾¯¸æ¡£

2.¶ÔµÚÒ»×÷Õß×£°®¶«£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ¡£

3.¶Ô²¢ÁеÚÒ»×÷ÕßËïÓ¯Ó¯¡¢ÂíÇï¾Õ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£

£¨Í¨±¨Á´½Ó£º£©

Ê®Èý¡¢É½¶«Ê¡¼ÃÄþÊеÚÒ»ÈËÃñÒ½ÔºÕÔÑåÄþΪͨѶ×÷Õß¡¢ÆëÓñçôΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄCBP?triggered KDM2B acetylation accelerates the carcinogenesis of colon cancer£¬¾­²é£¬Ïµ´æÔÚ´úдµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÕÔÑåÄþ£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬»º½ú1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£»È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬³·¸å£¬µ³ÄÚ¾¯¸æ¡£

2.¶ÔµÚÒ»×÷Õ߯ëÓñçô£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬»º½ú3Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬ÐÐÕþ¾¯¸æ¡£

£¨Í¨±¨Á´½Ó£º£©

Ê®ËÄ¡¢É½¶«Ê¡¼ÃÄþÊеÚÒ»ÈËÃñÒ½Ôº¿×µÂæ·ÎªÍ¨Ñ¶×÷Õß¡¢·¿ÀÚΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄIcariin inhibits cell proliferation, migration and invasion by down-regulation of microRNA-625-3p in thyroid cancer cells£¬¾­²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾ÝµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷Õß¿×µÂæ·£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬ÐÐÕþ¾¯¸æ¡£

2.¶ÔµÚÒ»×÷Õß·¿ÀÚ£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬µ³ÄÚ¾¯¸æ¡£

3.¶Ô²ÎÓë×÷ÕßÐìç⣺ȡÏû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ¡£

£¨Í¨±¨Á´½Ó£º£©

Ê®Î塢ɽ¶«Ê¡¼ÃÄþÊеÚÒ»ÈËÃñÒ½ÔºÑÕÍ¢ÕñΪͨѶ×÷Õß¡¢ÒÁ¹ãÀ¤ÎªµÚÒ»×÷Õß·¢±íµÄÂÛÎÄGinsenoside Rg1 defenses PC-12 cells against hydrogen peroxide-caused damage via up-regulation of miR-216a-5p£¬¾­²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³Ì¡¢²»µ±ÊðÃûµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÑÕÍ¢Õñ£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬µ³ÄÚ¾¯¸æ¡£

2.¶ÔµÚÒ»×÷ÕßÒÁ¹ãÀ¤£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ¡£

£¨Í¨±¨Á´½Ó£º£©

Ê®Áù¡¢É½¶«Ê¡¼ÃÄþÊеÚÒ»ÈËÃñÒ½ÔºÐìÏ×Â×ΪµÚÒ»¼æÍ¨Ñ¶×÷Õß·¢±íµÄÂÛÎÄRas-PI3K pathway promotes osteosarcoma progression via regulating VRK1-mediated H2A phosphorylation at threonine 120£¬¾­²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔµÚÒ»¼æÍ¨Ñ¶×÷ÕßÐìÏ×Â×£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬ÐÐÕþ¾¯¸æ¡£

2.¶Ô²ÎÓë×÷ÕßÓںƣº¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£

£¨Í¨±¨Á´½Ó£º£©

Ê®Æß¡¢É½¶«Ê¡¼ÃÄþÊеÚÒ»ÈËÃñÒ½ÔºÍõÐñΪͨѶ×÷Õß¡¢ÇØÎ¯Î¯ÎªµÚÒ»×÷Õß·¢±íµÄÂÛÎÄInhibiting lncRNA ROR suppresses growth, migration and angiogenesis in microvascular endothelial cells by up-regulating miR-26£¬¾­²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³Ì¡¢²»µ±ÊðÃûµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÍõÐñ£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬µ³ÄÚ¾¯¸æ¡£

2.¶ÔµÚÒ»×÷ÕßÇØÎ¯Î¯£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬ÊÕ»ØÂÛÎÄ¿ÆÑн±ÀøºÍÈÙÓþ³ÆºÅ£¬»ºÆ¸2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ¡£

3.¶Ô²ÎÓë×÷ÕßÀîÏþÑÞ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£

£¨Í¨±¨Á´½Ó£º£©

Ê®°Ë¡¢É½¶«Ê¡¼ÃÄþÊеÚÒ»ÈËÃñÒ½ÔºÃϽàΪͨѶ×÷Õß¡¢ÁõÐãϼΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄTanshinone IIA ameliorates lipopolysaccharide-induced inflammatory response in bronchial epithelium cell line BEAS-2B by down-regulating miR-27a£¬¾­²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³Ì¡¢´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÃϽࣺȡÏû7ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû7Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú3Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬ÐÐÕþ¾¯¸æ£¬Ãâ³ý¸±»¤Ê¿³¤Ö°Îñ¡£

2.¶ÔµÚÒ»×÷ÕßÁõÐãϼ£ºÈ¡Ïû8ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû8Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬×·»Ø×÷Õ߸öÈËËùµÃµÄÂÛÎÄ¿ÆÑн±ÀøºÍÈÙÓþ³ÆºÅ£¬³·ÏúÒÑÈ¡µÃµÄ¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£»»º½ú5Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ£¬Ãâ³ý¸±»¤Ê¿³¤Ö°Îñ¡£

£¨Í¨±¨Á´½Ó£º£©

Ê®¾Å¡¢É½¶«Ê¡¼ÃÄþÊеÚÒ»ÈËÃñÒ½ÔºÕÅÏþ·ÒΪͨѶ×÷Õߣ¬ÕŹú²ý¡¢µÔéªÎª¹²Í¬µÚÒ»×÷Õß·¢±íµÄÂÛÎÄAlkannin represses growth of pancreatic cancer cells based on the down regulation of miR?199a£¬¾­²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÕÅÏþ·Ò£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬µ³ÄÚ¾¯¸æ¡£

2.¶ÔµÚÒ»×÷ÕßÕŹú²ý£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬µ³ÄÚ¾¯¸æ¡£

3.¶Ô²¢ÁеÚÒ»×÷ÕßµÔ骣º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£

£¨Í¨±¨Á´½Ó£º£©

¶þÊ®¡¢É½¶«Ê¡¼ÃÄþÊеÚÒ»ÈËÃñÒ½ÔºÆëÓñçôΪͨѶ×÷Õß¡¢Àî½ðÁ¼ÎªµÚÒ»×÷Õß·¢±íµÄÂÛÎÄGinsenoside Rg3 inhibits cell growth, migration and invasion in Caco-2 cells by downregulation of lncRNA CCAT1£¬¾­²é£¬Ïµ´æÔÚ´úдµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷Õ߯ëÓñçô£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬»º½ú3Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬³·¸å£¬ÐÐÕþ¾¯¸æ¡£

2.¶ÔµÚÒ»×÷ÕßÀî½ðÁ¼£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð­»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ¡£

£¨Í¨±¨Á´½Ó£º£©

¶þʮһ¡¢É½¶«Ê¡¼ÃÄÏÊÐÖÐÐÄҽԺʯѧ·åΪͨѶ×÷Õß¡¢ºÊÔóÊÐÁ¢Ò½ÔºÓÚ´¨¶«ÎªµÚÒ»×÷Õß·¢±íµÄÂÛÎÄLong noncoding RNA CHRF exacerbates IL?6?induced inflammatory damages by downregulating microRNA?146a in ATDC5 cells£¬¾­²é£¬Ïµ´æÔÚʵÑéͼƬ´Û¸ÄµÄѧÊõ²»¶ËÐÐΪ¡£

1.¼ÃÄÏÊÐÖÐÐÄÒ½Ôº¶ÔͨѶ×÷Õßʯѧ·å×÷³öÈçÏ´¦Àí£ºÔð³É³·¸å¡¢¿ÆÑгÏÐŽëÃã̸»°¡¢ÊÕ»ØÂÛÎÄ·¢±íÒѱ¨ÏúµÄÏà¹Ø·ÑÓúͽ±Àø×ʽð¡¢È¡Ïû5ÄêÄÚÖ°³ÆÆ¸ÈÎ×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨¸÷Àà¿ÆÑн±Àø×ʸñ¡¢È¡Ïû5ÄêÉ걨¸÷ÀàÏÞÏî¿ÆÑÐÏîÄ¿µÄ×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨¸÷¼¶¿Æ¼¼È˲ŵÄ×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨Ñо¿Éúµ¼Ê¦×ʸñ¡£

2.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔµÚÒ»×÷ÕßÓÚ´¨¶«×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°¡¢Í¨±¨ÅúÆÀ¡¢Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£

£¨Í¨±¨Á´½Ó£º£©

¶þÊ®¶þ¡¢É½¶«Ê¡¼ÃÄÏÊÐÖÐÐÄÒ½Ôº¼ÖÌúêΪͨѶ×÷Õß¡¢±õÖÝҽѧԺ¸½ÊôÒ½ÔºÍõÕ×ÁÖΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄlong noncoding RNA maternally expressed gene 3 knockdown alleviates lipopolysaccharide-induced inflammatory injury by up-miR-203 in ATDCS cells£¬¾­²é£¬Ïµ´æÔÚʵÑéͼƬ´Û¸ÄµÄѧÊõ²»¶ËÐÐΪ¡£

1.¼ÃÄÏÊÐÖÐÐÄÒ½Ôº¶ÔͨѶ×÷Õß¼ÖÌúê×÷³öÈçÏ´¦Àí£ºÔð³É³·¸å¡¢¿ÆÑгÏÐŽëÃã̸»°¡¢ÊÕ»ØÉæÏÓÂÛÎÄ·¢±íÒѱ¨ÏúµÄÏà¹Ø·ÑÓúͽ±Àø×ʽð¡¢È¡Ïû5ÄêÄÚÉ걨¸÷Àà¿ÆÑн±Àø×ʸñ¡¢È¡Ïû5ÄêÉ걨¸÷ÀàÏÞÏî¿ÆÑÐÏîÄ¿µÄ×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨¸÷¼¶¿Æ¼¼È˲ŵÄ×ʸñ¡¢È¡Ïû5ÄêÄÚÑо¿Éúµ¼Ê¦ÕÐÉú×ʸñ¡£

2.±õÖÝҽѧԺ¸½ÊôÒ½Ôº¶ÔµÚÒ»×÷ÕßÍõÕ×ÁÖ×÷³öÈçÏ´¦Àí£ºÈ¡ÏûÆäÉêÇ벩ʿѧλ×ʸñ¡£

£¨Í¨±¨Á´½Ó£º£©

¶þÊ®Èý¡¢É½¶«Ê¡¼ÃÄÏÊÐÖÐÐÄÒ½ÔºÕÅÇì¹úΪͨѶ×÷Õß¡¢ÁõÊçºãΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄgreen tea polyphenols protect PC12 cells against H2O2-induced damages by upregulating IncRNA MALATI£¬¾­²é£¬ÏµÎªÍ¨Ñ¶×÷Õß´Û¸ÄʵÑéͼƬµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÕÅÇì¹ú£ºÔð³É³·¸å¡¢¿ÆÑгÏÐŽëÃã̸»°¡¢ÊÕ»ØÉæÏÓÂÛÎÄ·¢±íÒѱ¨ÏúµÄÏà¹Ø·ÑÓúͽ±Àø×ʽð¡¢È¡Ïû5ÄêÄÚÉ걨¸÷Àà¿ÆÑн±Àø×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨¸÷ÀàÏÞÏî¿ÆÑÐÏîÄ¿µÄ×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨¸÷¼¶¿Æ¼¼È˲ŵÄ×ʸñ¡£

2.¶ÔµÚÒ»×÷ÕßÁõÊçºã£º½ëÃã̸»°¡£

£¨Í¨±¨Á´½Ó£º£©

¶þÊ®ËÄ¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½ÔºËïÐÂÑÒΪͨѶ×÷Õß¡¢Û²³ÇÏØÈËÃñҽԺǮµÀÁÖΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄNotoginsenoside R1 protects WI-38 cells against lipopolysaccharide-triggered injury via adjusting miR-181a/TLR4 axis£¬¾­²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£

1.ºÊÔóÊÐÁ¢Ò½ÔºÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

£¨1£©¶ÔͨѶ×÷ÕßËïÐÂÑÒ£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£

£¨2£©¶ÔÆäËû×÷ÕßÉÛÏÍÀ¤£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£

2.Û²³ÇÏØÈËÃñÒ½Ôº¶ÔµÚÒ»×÷ÕßÇ®µÀÁÖ×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£»Í¨±¨ÅúÆÀ£»È¡Ïû²Î¼Ó2021Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ£¬±¾Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡Ïû5ÄêÄڿƼ¼¼Æ»®ÏîÄ¿É걨×ʸñ¡£

3.ºÊÔóÊеÚÈýÈËÃñÒ½ÔºÆäËû×÷ÕßÀîÓ­´º×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬1ÄêÄÚÈ¡ÏûÉêÇë»òÉ걨¿ÆÑмƻ®ÏîÄ¿×ʸñ¡£

£¨Í¨±¨Á´½Ó£º£©

¶þÊ®Î塢ɽ¶«Ê¡ºÊÔóÊÐÁ¢Ò½ÔºÑî´ºÇäΪͨѶ×÷Õß¡¢Û²³ÇÏØÈËÃñÒ½ÔºËΰ®Æ½ÎªµÚÒ»×÷Õß·¢±íµÄÂÛÎÄLong noncoding RNA Alu?mediated p21 transcriptional regulator promotes proliferation, migration, and pipe-formation of human microvascular endothelial cells by sponging miR?126£¬¾­²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£

1.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

£¨1£©¶ÔͨѶ×÷ÕßÑî´ºÇ䣺³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£

£¨2£©¶ÔÆäËû×÷Õß·ëÈߣº¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£

2.Û²³ÇÏØÈËÃñÒ½Ôº¶ÔµÚÒ»×÷ÕßËΰ®Æ½×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£»Í¨±¨ÅúÆÀ£»È¡Ïû²Î¼Ó2021Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ£¬±¾Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡Ïû5ÄêÄڿƼ¼¼Æ»®ÏîÄ¿É걨×ʸñ¡£

£¨Í¨±¨Á´½Ó£º£©

¶þÊ®Áù¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½ÔºÍõ½ðÁúΪͨѶ×÷Õß¡¢ÌÆÊØÒåΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄLong noncoding RNA MEG3 deteriorates inflammatory damage by downregulating microRNA-101a£¬¾­²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÍõ½ðÁú£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£

2.¶ÔµÚÒ»×÷ÕßÌÆÊØÒå¡¢ÆäËû×÷Õߺ«¾ýϼ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл4Äê¡£

3.¶ÔÆäËû×÷Õß½¹»Û¡¢ÁõÓ±Ó±£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£

4.¶ÔÆäËû×÷Õß˾æºÄÈ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл6Äê¡£

£¨Í¨±¨Á´½Ó£º£©

¶þÊ®Æß¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½Ôº¿µ¾²ÎªÍ¨Ñ¶×÷Õß¡¢ÁõӱΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄCircular RNA ACR relieves high glucose?aroused RSC96 cell apoptosis and autophagy via declining microRNA-145-3p£¬¾­²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£

1.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

£¨1£©¶ÔͨѶ×÷Õß¿µ¾²£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£

£¨2£©¶ÔµÚÒ»×÷ÕßÁõÓ±£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£

£¨3£©¶ÔÆäËû×÷Õß³ÂÏþÇ죺¿ÆÑгÏÐŽëÃã̸»°£¬ÔÚͨ±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл1Äê¡£

2.ºÊÔóÊд«È¾²¡Ò½Ôº¶ÔÆäËû×÷ÕßÒ¦¾§¾§×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹¿ÆÑл1Ä꣬1ÄêÄÚÈ¡ÏûÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺźÍÍÆ³Ù1Äêרҵ¼¼ÊõÖ°Îñ½úÉýµÈ×ʸñ¡£

£¨Í¨±¨Á´½Ó£º£©

¶þÊ®°Ë¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½ÔºË¾æºÄÈΪͨѶ×÷Õߣ¬ÁijÇÊÐÈËÃñÒ½ÔºÕÅÑ©ËÉ¡¢¶­»ªÎ°Îª¹²Í¬µÚÒ»×÷Õß·¢±íµÄÂÛÎÄTetramethylpyrazine partially relieves hypoxia-caused Damage of cardiomyocytes H9C2 by downregulation of mir-449a£¬¾­²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£

1.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

£¨1£©¶ÔͨѶ×÷Õß˾æºÄÈ£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл6Äê¡£

£¨2£©¶ÔÆäËû×÷Õߺ«¾ýϼ¡¢ÌÆÊØÒ壺¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл4Äê¡£

2.ÁijÇÊÐÈËÃñÒ½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

£¨1£©¶ÔµÚÒ»×÷ÕßÕÅÑ©ËÉ£º¿ÆÑгÏÐŽëÃã̸»°£¬5ÄêÄÚÈ¡Ïûרҵ¼¼ÊõÖ°ÎñÉ걨ºÍƸÈÎ×ʸñ£¬5ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬5ÄêÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬¼ÇÈë¿ÆÑгÏÐÅʧÐŵµ°¸¡£

£¨2£©¶ÔµÚÒ»×÷Õß¶­»ªÎ°£º¿ÆÑгÏÐŽëÃã̸»°£»½µ¼¶£¬´Ó¸±Ö÷ÈÎҽʦ½µÎªÖ÷ÖÎҽʦ£»³·Ïú»ñµÃµÄ¸±Ö÷ÈÎҽʦְ³Æ£¬3ÄêÄÚÈ¡Ïûרҵ¼¼ÊõÖ°ÎñÉ걨ºÍƸÈÎ×ʸñ£»3ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£»3ÄêÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»¼ÇÈë¿ÆÑгÏÐÅʧÐŵµ°¸¡£

£¨3£©¶ÔÆäËû×÷ÕßÁõÓ£º1ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺźÍרҵ¼¼ÊõÖ°Îñ½úÉýµÈ×ʸñ¡£

£¨Í¨±¨Á´½Ó£º£©

¶þÊ®¾Å¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½ÔºÕÔº£ÍúΪͨѶ×÷Õß¡¢Û²³ÇÏØÈËÃñÒ½Ôº¸ßÏÍÈñΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄK-Ras-PI3K regulates H3K56ac through PCAF to elevate the occurrence and growth of liver cancer£¬¾­²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£

1.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

£¨1£©¶ÔͨѶ×÷ÕßÕÔº£Íú£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£

£¨2£©¶ÔÆäËû×÷Õß³ÌÕ×Á¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл1Äê¡£

£¨3£©¶ÔÆäËû×÷ÕßÔ¬º£·æ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл6Äê¡£

2.Û²³ÇÏØÈËÃñÒ½Ôº¶ÔµÚÒ»×÷Õ߸ßÏÍÈñ×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£»Í¨±¨ÅúÆÀ£»È¡Ïû²Î¼Ó2021Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ£¬±¾Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡Ïû5ÄêÄڿƼ¼¼Æ»®ÏîÄ¿É걨×ʸñ¡£

£¨Í¨±¨Á´½Ó£º£©

ÈýÊ®¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½Ôº¸¶Ô£ÎªÍ¨Ñ¶×÷Õß¡¢Û²³ÇÏØÈËÃñÒ½ÔºÕŽ¨»ªÎªµÚÒ»×÷Õß·¢±íµÄÂÛÎÄHOTAIR regulates lipopolysaccharide?induced inflammatory response in hepatocytes£¬¾­²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£

1.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

£¨1£©¶ÔͨѶ×÷Õ߸¶Ô££º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£

£¨2£©¶ÔÆäËû×÷Õß³Âíµ¡¢µÔÓñÑࣺ¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£

2.Û²³ÇÏØÈËÃñÒ½Ôº¶ÔµÚÒ»×÷ÕßÕŽ¨»ª×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£»Í¨±¨ÅúÆÀ£»È¡Ïû²Î¼Ó2021Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ£¬±¾Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡Ïû5ÄêÄڿƼ¼¼Æ»®ÏîÄ¿É걨×ʸñ¡£

£¨Í¨±¨Á´½Ó£º£©

Èýʮһ¡¢É½¶«Ê¡×Ͳ©ÊÐÁÙ×ÍÇøÈËÃñÒ½ÔºÍõÌÎΪͨѶ×÷Õß¡¢×Ͳ©ÊÐÖÐÐÄÒ½ÔºÉлªÎªµÚÒ»×÷Õß·¢±íµÄÂÛÎÄOver-expression of DJ-1 attenuates effects of curcumin on colorectal cancer cell proliferation and apotisis¡£¾­²é£¬Ïµ´æÔÚ´úд²¢·¢±íµÄѧÊõ²»¶ËÐÐΪ¡£

1.ͨѶ×÷ÕßÍõÌÎÂÛÎÄ·¢±íʱ¾ÍÖ°ÓÚÁÙ×ÍÇøÈËÃñÒ½Ôº£¬ÏÖ¾ÍÖ°ÓÚ×Ͳ©ÊÐÖÐÐÄÒ½Ôº¡£ÁÙ×ÍÇøÈËÃñÒ½ÔººÍ×Ͳ©ÊÐÖÐÐÄÒ½Ôº¶ÔÍõÌÎ×÷³öÈçÏ´¦Àí£º³·¸å£¬ÊÕ»ØÂÛÎĽ±½ð½±Àø£¬5ÄêÄÚ²»µÃÉ걨ʡ¼¶¹ú¼Ò¼¶¿ÆÑпÎÌâºÍ¿ÆÑгɹû½±Àø£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Ä꣬»ºÆ¸1Ä꣬ȡÏûÄê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£

2.×Ͳ©ÊÐÖÐÐÄÒ½Ôº¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦Àí£º

£¨1£©¶ÔµÚÒ»×÷ÕßÉлª£ºÈ¡Ïû5ÄêÄÚÊ¡¼¶¡¢¹ú¼Ò¼¶¿ÆÑÐÏîÄ¿¼°¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ¿ÆÑгÏÐŽëÃã̸»°´¦£¬Í¨±¨ÅúÆÀ£»»ºÆ¸1ÄꣻȡÏûÄê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£

£¨2£©¶ÔÆäËû×÷ÕßÀîÃô¡¢ÂÞÓ¨¡¢»ÆÀ¤Ã÷£ºÈ¡Ïû3ÄêÄÚÊ¡¼¶¡¢¹ú¼Ò¼¶¿ÆÑÐÏîÄ¿¼°¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡Ïû3Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1Äꣻ¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»»ºÆ¸1ÄꣻȡÏûÄê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£

£¨Í¨±¨Á´½Ó£º£©

ÈýÊ®¶þ¡¢É½¶«Ê¡±õÖÝÊÐÈËÃñÒ½Ôº¸¶ÑÞΪͨѶ×÷Õß¡¢±ÏÒæÃ÷ΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄSchizandrin A exerts anti-tumor effects on A375 cells¡¡by down-regulating H19¡£¾­²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷Õ߸¶ÑÞ¡¢µÚÒ»×÷Õß±ÏÒæÃ÷£º¿ÆÑгÏÐŽëÃã̸»°£»È¡Ïû5ÄêÄÚÉêÇëºÍÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺš¢×¨Òµ¼¼ÊõÖ°Îñ½úÉýÒÔ¼°Ñ§Êõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±µÈ×ʸñ£¬È¡Ïû5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÐÐÕþ¾¯¸æ£»³·¸å¡£

2.¶ÔÆäËû×÷ÕßÍõÊçÑà¡¢³ÂÐËÐã¡¢²ÌСƼ£º¿ÆÑгÏÐŽëÃã̸»°£»È¡Ïû1ÄêÄÚÉêÇëºÍÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺš¢×¨Òµ¼¼ÊõÖ°Îñ½úÉýÒÔ¼°Ñ§Êõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±µÈ×ʸñ£¬È¡Ïû1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ¡£

£¨Í¨±¨Á´½Ó£º.cn/lzzc/5256.jhtml?£©

ÈýÊ®Èý¡¢É½¶«Ê¡ÁijÇÊеÚÈýÈËÃñÒ½ÔºÀîѧ¸£ÎªÍ¨Ñ¶ºÍµÚÒ»×÷Õß·¢±íµÄÂÛÎÄTripterine up-regulates miR-223 to alleviate lipopolyaccharide-induced damage in murine chondrogenic ATDC5 cells¡£¾­²é£¬Ïµ´æÔÚÂòÂô¡¢´úдÂÛÎĵÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º

1.¶ÔµÚÒ»¼æÍ¨Ñ¶×÷ÕßÀîѧ¸££º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬5ÄêÄÚÈ¡ÏûÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ð£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺŵÈ×ʸñ£¬Í£Ö¹É걨²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Ä꣬5ÄêÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ¡£

2.¶ÔÆäËû×÷ÕßκΡ¡¢ÕÔÖÒÈ«¡¢ÂÀÊ÷Õñ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹É걨²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ»î¶¯1Äê¡£

£¨Í¨±¨Á´½Ó£º£©

ÈýÊ®ËÄ¡¢É½¶«Ê¡ÁijÇÊÐÈËÃñÒ½ÔºµÔºìÑåΪͨѶ×÷Õß¡¢ãÆÈðºìΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄMicroRNA?150?5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAFV600E mutation in papillary thyroid cancer cells£¬¾­²é£¬Ïµ´æÔÚÂòÂôÂÛÎĵÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßµÔºìÑ壺8ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬8ÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬¼ÇÈë¿ÆÑгÏÐÅÐÅÓÃÐÅϢϵͳ£¬³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬È¡Ïû¸±Ö÷ÈÎҽʦƸÈÎ×ʸñ½µÆ¸ÎªÖ÷ÖÎҽʦ¡£

2.¶ÔµÚÒ»×÷ÕßãÆÈðºì£º6ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬6ÄêÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬¼ÇÈë¿ÆÑгÏÐÅÐÅÓÃÐÅϢϵͳ£¬¿ÆÑгÏÐŽëÃã̸»°£¬È¡ÏûÖ÷ÈÎҽʦƸÈÎ×ʸñ½µÆ¸Îª¸±Ö÷ÈÎҽʦ¡£

£¨Í¨±¨Á´½Ó£º£©

ÈýÊ®Î塢ɽ¶«Ê¡ÁijÇÊÐÈËÃñÒ½ÔºÁõî£æÃΪͨѶ×÷Õß¡¢ÍõÃôΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄCXCL16 protects against oxygen and glucose deprivation?induced injury in human microvascular endothelial cells?1: Potential role in ischemic stroke£¬¾­²é£¬Ïµ´æÔÚÂòÂôÂÛÎĵÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÁõî£æÃ£º3ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬3ÄêÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬¼ÇÈë¿ÆÑгÏÐÅÐÅÓÃÐÅϢϵͳ£¬³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬È¡Ïû¸±Ö÷ÈÎҽʦƸÈÎ×ʸñ½µÆ¸ÎªÖ÷ÖÎҽʦ¡£

2.¶ÔµÚÒ»×÷ÕßÍõÃô£º5ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬5ÄêÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬¼ÇÈë¿ÆÑгÏÐÅÐÅÓÃÐÅϢϵͳ£¬¿ÆÑгÏÐŽëÃã̸»°£¬È¡Ïû¸±Ö÷ÈÎҽʦƸÈÎ×ʸñ½µÆ¸ÎªÖ÷ÖÎҽʦ¡£

£¨Í¨±¨Á´½Ó£º£©

ÈýÊ®Áù¡¢É½¶«Ê¡ÁijÇÊÐÈËÃñÒ½ÔºÑîÌìÕýΪͨѶ×÷Õß¡¢µÔºìÑåΪµÚÒ»×÷Õß·¢±íµÄÂÛÎÄLncRNA BCAR4 up-regulates EGFR and thus promotes human thyrocyte proliferation£¬¾­²é£¬Ïµ´æÔÚÂòÂôÂÛÎĵÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º

1.¶ÔͨѶ×÷ÕßÑîÌìÕý£º4ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬4ÄêÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬¼ÇÈë¿ÆÑгÏÐÅÐÅÓÃÐÅϢϵͳ£¬³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬È¡Ïû3ÄêÖ°³Æ½úÉý×ʸñ¡£

2.¶ÔµÚÒ»×÷ÕßµÔºìÑ壺8ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬8ÄêÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬¼ÇÈë¿ÆÑгÏÐÅÐÅÓÃÐÅϢϵͳ£¬³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬È¡Ïû¸±Ö÷ÈÎҽʦƸÈÎ×ʸñ½µÆ¸ÎªÖ÷ÖÎҽʦ¡£

£¨Í¨±¨Á´½Ó£º£©

Ïà¹ØµÄÖ÷ÌâÎÄÕ£º

ÀûÀ´¹ú¼ÊÊÖ»úÏÂÔØ ÀûÀ´¹Ù·½ÍøÕ¾w66À

{Copyright 2017 ÀûÀ´¹ú¼ÊÊÖ»úÏÂÔØ All Rights Reserved